openPR Logo
Press release

Alport Syndrome Clinical Landscape, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Enyo Pharma, Bayer

11-03-2025 08:24 PM CET | Associations & Organizations

Press release from: ABNewswire

Alport Syndrome Clinical Landscape

Alport Syndrome Clinical Landscape

DelveInsight's, "Alport Syndrome - Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Alport Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Alport Syndrome pipeline features over 4 key pharmaceutical companies actively engaged in developing more than 6 therapeutic candidates aimed at treating this rare disorder.

Alport Syndrome Overview:

Alport syndrome is a rare genetic disorder that affects roughly 1 in 50,000 individuals and is primarily characterized by microscopic hematuria and progressive chronic kidney disease (CKD), often accompanied by hearing and ocular abnormalities.

The disease results from mutations in the COL4A3, COL4A4, and COL4A5 genes, which impair the normal formation of the 3-4-5 collagen IV network-a crucial structural component of the basement membranes in the kidneys, inner ear, and eyes.

Early clinical signs, including hematuria, proteinuria, and edema, are often nonspecific, leading to frequent misdiagnosis with other kidney disorders. As the disease progresses, renal function deteriorates, leading to CKD or end-stage renal disease (ESRD).

Beyond the kidneys, sensorineural hearing loss commonly develops in childhood or adolescence and worsens over time. Ocular abnormalities such as anterior lenticonus and retinal changes are also observed, though these typically cause milder visual impairment.

At the molecular level, the disruption of type IV collagen synthesis weakens the structural integrity of basement membranes, resulting in thinning, splitting, and scarring that impair filtration in the kidneys and disrupt cochlear and ocular function-underlying the triad of renal, auditory, and ocular symptoms seen in Alport syndrome.

Request for a detailed insights report on Alport Syndrome pipeline insights https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

DelveInsight's "Alport Syndrome Pipeline Insight 2025" report offers an in-depth evaluation of the current clinical development landscape and future growth opportunities within the Alport Syndrome therapeutics market.

Key Takeaways from the Alport Syndrome Pipeline Report

*
DelveInsight's Alport Syndrome pipeline report highlights an active landscape with over four companies engaged in developing six or more therapeutic candidates for the treatment of Alport Syndrome.

*
In January 2024, Enyo Pharma obtained FDA clearance for its Investigational New Drug (IND) application to initiate a Phase II clinical trial (ALPESTRIA-1) evaluating Vonafexor in patients with Alport Syndrome.

*
Leading companies such as Enyo Pharma, Bayer, and others are advancing innovative therapies aimed at enhancing the Alport Syndrome treatment landscape.

*
Notable candidates currently in development include Vonafexor, BAY 3401016, and additional promising therapies.

Alport Syndrome Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Alport Syndrome Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alport Syndrome treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alport Syndrome market.

Download our free sample page report on Alport Syndrome pipeline insights https://www.delveinsight.com/sample-request/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Alport Syndrome Emerging Drugs

Vonafexor - Enyo Pharma

Vonafexor (EYP001), developed by Enyo Pharma, is an investigational treatment targeting kidney disorders such as Alport syndrome and chronic kidney disease (CKD). It is a synthetic, non-steroidal, non-bile acid farnesoid X receptor (FXR) agonist with exceptional selectivity for FXR and no activity on the bile acid receptor TGR5. Distinct from other FXR agonists, Vonafexor's unique molecular structure induces a differentiated gene expression profile influenced by its ligand-binding behavior. The therapy is currently being evaluated in Phase II clinical trials for Alport syndrome.

BAY 3401016 - Bayer

BAY 3401016, also known as SEMA 3A, is a monoclonal antibody developed by Bayer in collaboration with Evotec SE. It targets and inhibits semaphorin 3A (SEMA3A), a protein that plays a key role in neuronal signaling and immune system regulation. The therapy is currently in Phase I clinical development for the treatment of Alport syndrome.

Alport Syndrome Companies

Around four or more major companies are actively engaged in developing therapies for Alport Syndrome. Among these, Enyo Pharma leads with a drug candidate that has progressed to the most advanced stage-Phase II clinical development.

DelveInsight's report covers around 75+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Alport Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Alport Syndrome Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Alport Syndrome Therapies and Key Companies: Alport Syndrome Clinical Trials and advancements https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Alport Syndrome Pipeline Therapeutic Assessment

- Alport Syndrome Assessment by Product Type

- Alport Syndrome By Stage

- Alport Syndrome Assessment by Route of Administration

- Alport Syndrome Assessment by Molecule Type

Download Alport Syndrome Sample report to know in detail about the Alport Syndrome treatment market @ Alport Syndrome Therapeutic Assessment https://www.delveinsight.com/sample-request/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Request the Sample PDF to Get Detailed Insights About the Alport Syndrome Pipeline Reports Offerings https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alport-syndrome-clinical-landscape-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-enyo-pharma-bayer]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alport Syndrome Clinical Landscape, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Enyo Pharma, Bayer here

News-ID: 4251709 • Views:

More Releases from ABNewswire

Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, A
Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treat …
DelveInsight's, "Pulmonary Fibrosis - Pipeline Insight, 2025" report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. DelveInsight's analysis highlights that the Pulmonary Fibrosis pipeline features over
Irritable Bowel Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Tryp Therapeutics, CinRx Pharma, Otsuka Pharmaceutical, RaQualia Pharma, Biomi
Irritable Bowel Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, …
DelveInsight's, "Irritable Bowel Syndrome - Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Irritable Bowel Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, the Irritable Bowel Syndrome (IBS)
Dengue Fever Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Johnson & Johnson, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Panacea Biotec,
Dengue Fever Clinical, Companies, Therapeutic Assessment, Therapies, Treatment A …
DelveInsight's, "Dengue Fever - Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, the Dengue Fever pipeline includes 8+ key
Toll-Like Receptor 8 (TLR8) Agonist Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eikon Therapeutics, Gilead Sciences, Inimmune, Astante Therapeutics
Toll-Like Receptor 8 (TLR8) Agonist Clinical, Companies, Therapeutic Assessment, …
DelveInsight's, "Toll-Like Receptor 8 Agonist - Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Toll-Like Receptor 8 Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, the Toll-Like Receptor

All 5 Releases


More Releases for Alport

Alport Syndrome Market is Expected to Reach $4.5 Billion by 2034
Alport syndrome is a rare genetic kidney disorder caused by mutations in the COL4A3, COL4A4, or COL4A5 genes, which affect the production of type IV collagen in the basement membranes of the kidneys, inner ear, and eyes. The condition leads to progressive renal disease, hearing loss, and ocular abnormalities, with most patients eventually developing kidney failure requiring dialysis or transplantation. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71647 Traditionally, treatment
Alport Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medication, …
Alport Syndrome companies are Eloxx Pharmaceuticals, River 3 Renal Corp, Chinook Therapeutics, Travere Therapeutics, Reata Pharmaceuticals, and others. Alport Syndrome Market Summary The Alport syndrome market in the 7MM was valued at around USD 20 million in 2023 and is projected to grow by 2034. The disorder is primarily X-linked, accounting for 80% of cases, with 90% of males progressing to kidney failure by age 40 if untreated. In 2023, the US
Alport Syndrome Clinical, Companies, Therapeutic Assessment, Therapies, Treatmen …
Alport Syndrome Pipeline constitutes 4+ key companies continuously working towards developing 6+ Alport Syndrome treatment therapies, analyzes DelveInsight. Alport Syndrome Overview: Alport syndrome is a rare inherited disorder, affecting approximately 1 in 50,000 people, and is most often characterized by microscopic hematuria and progressive chronic kidney disease (CKD), along with complications beyond the kidneys. The condition arises from mutations in the COL4A3, COL4A4, and COL4A5 genes, which interfere with the normal assembly
Alport Syndrome Market Size, Share, Trends, Industry Growth and Competitive Anal …
Data Bridge Market Research analyses a growth rate in the global alport syndrome market in the forecast period 2022-2029. Market Definition Alport syndrome is the rare, genetic, inherited X-linked disorder caused by the gene mutation of COL4A3, COL4A4, or COL4A5. It is a condition that damages the tiny blood vessels of the kidney, that leads to kidney damage & failure. It also causes hearing loss and eye abnormalities. Patients suffering from this
Novel Therapeutic Modalities Transforming the Alport Syndrome Treatment Market 2 …
According to the research report, the global alport syndrome treatment market was valued at USD 12.26 million in 2022 and is expected to reach USD 19.00 million by 2032, to grow at a CAGR of 4.5% during the forecast period. Polaris Market Research recently launched the latest update on Alport Syndrome Treatment Market: By Size, Trends, Share, Growth, Segments, Industry Analysis and Forecast, 2032 that gives an extensive outlook of the
Alport Syndrome Treatment Market Research Reports, Industry Size, Growth Opportu …
Polaris Market Research has recently published an insightful research study titled Alport Syndrome Treatment Market: By Size, Trends, Share, Growth, Segments, Industry Analysis and Forecast, 2032, providing a comprehensive analysis of the market structure based on usage and type. The report evaluates the Alport Syndrome Treatment Market size and share by conducting a thorough examination within a specific timeframe. With a focus on the market, the study delves into consumption